All Stories

Jazz hands over $935M to buy Chimerix for near-approval cancer drug

Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO voiced an interest in diversifying the pipeline.

Mar 5, 2025 - 14:27
 0
Jazz hands over $935M to buy Chimerix for near-approval cancer drug
Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO voiced an interest in diversifying the pipeline.
Read More

Tags:

Previous Article

iDealwine hails strong year as it anticipates 2025 opening of New York office

Next Article

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab,...

Related Posts

Corbus posts first US data on challenger to Pfizer’s ADC Padcev

Corbus posts first US data on challenger to Pfizer’s AD...

Feb 14, 2025  0

Boehringer widens fibrosis drug's approval path after boosting lung function in 2nd phase 3 trial

Boehringer widens fibrosis drug's approval path after b...

Feb 10, 2025  0

Paragonix’s donor kidney perfusion system completes commercial flight

Paragonix’s donor kidney perfusion system completes com...

Mar 3, 2025  0